Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares

Bulletin Express

2025/10/27

Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.

Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1110273823"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110273823\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110273823?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110273823","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.</p>\n<p>Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-27 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.</p>\n<p>Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1110273823","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110273823","pubTimestamp":1761565398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药(01672)公布购回股份及更新已发行股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.\nHistorical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}